The global cancer diagnostics market to reach US$ 136.3 Bn in 2029 growing at compound annual growth rate (CAGR) of 6.1% during the forecast period from 2021 to 2029. The prime factors driving the global cancer diagnostics market is the rising prevalence of cancer worldwide. As per the World Health Organization (WHO), cancer accounted for the second leading cause of mortality, claiming to 8.8 million deaths in 2015 globally. The National Cancer Institute estimated around 1,685,210 new cancer cases in 2019 in the United States. As per the Centers for Disease Control and Prevention (CDC), cancer cases anticipated to increase by 2 million each year by 2020.
The medical marijuana market is set to reach US$ 57,582.5 Mn by 2026 from US$ 13,908.7 Mn in 2017 at a compound annual growth rate (CAGR) of 17.1% during the forecast period from 2018 to 2026. According to the International Association for the Study of Pain (IASP) any pain persisting for more than six months in defined as chronic pain.
The global cervical cancer diagnostic test market is growing significantly, was valued at US$ 8,779.2 Mn in 2017 and expected to attain US$ XX Mn by 2026. Worldwide growing prevalence of cervical cancer along with growing female population aged between 25 to 60 years are the major factors driving the overall growth of the global cervical cancer diagnostic test market.
The global nanoemulsion market projected to reach US$ 14,760.4 Mn by 2026 from US$ 6,827.5 Mn in 2017, growing at a CAGR of 8.9% during the forecast period from 2018 to 2026. Technically nanoemulsions are thermodynamically stable, isotropic, translucent or transparent, and dispersions of oil & water stabilized with a film linking surfactant molecules with a droplet size of 20 to 500nm.
The global blood flow measurement devices market accounted for a value of US$ Mn in 2017 and expected to attain US$ Mn by 2026. Drivers responsible for the market growth are globally growing elderly population coupled with rising prevalence of chronic diseases, increasing preference from users for noninvasive devices, and mounting technological developments in blood flow meters.
The global endobronchial ultrasound biopsy devices market accounted for a value of US$ 492.0 Mn in 2017 and expected to attain US$ 753.6 Mn by 2026. Worldwide growing elderly population coupled with increasing prevalence of respiratory diseases such as chronic obstructive pulmonary disease (COPD), lung cancer, pleural mesothelioma, and tuberculosis (TB) anticipated to foster the market growth over the forecast period.
The global blood-brain barrier market projected to reach US$ 5,704.2 Mn by 2026 from US$ 696.4 Mn in 2017, growing at a CAGR of 25.0% during the forecast period from 2018 to 2026. The blood-brain barrier (BBB) prevents free flow of elements from circulatory system to the cerebrospinal fluid (CSF) or brain with specific exchange of elements regulated by blood-brain barrier and blood-CSF barrier.
The oncology biosimilars market stood at US$ 3520.9 Mn in 2021 and projected to exhibit a double-digit compound annual growth rate (CAGR) of 28.3% during the forecast period from 2025 to 2033. According to U.S. Food and Drug Administration, biosimilars are biological medicines that contain a highly similar version of the active substance of an already approved biologic, commonly referred to as the reference product.
Single photon emission computed tomography (SPECT) is a form of non-invasive nuclear medicine tomographic imaging technique that utilizes gamma rays to provide 3D information of body organs (inside view). This system uses a radioactive substance and a special camera to create 3-D pictures which display the blood flow to tissues & organs thereby assisting doctors to diagnose or monitor brain disorders, bone disorders, and heart problems.
The global medical imaging software market is projected to grow at a CAGR of 7.2% during the forecast period of 2025 to 2033, driven by factors such as the increasing prevalence of chronic diseases, advancements in imaging technology, and the rising demand for efficient and accurate diagnostic solutions. This market encompasses software solutions that are crucial in acquiring, processing, visualizing, and analyzing medical images. These solutions enable healthcare professionals to effectively diagnose and treat various medical conditions by creating visual representations of the internal structures of the body.
The oncology drugs market includes pharmaceutical products and advanced therapies used to treat cancer. Major treatment classes include chemotherapy, targeted therapy, immunotherapy, hormonal therapy, monoclonal antibodies, antibody-drug conjugates, cancer vaccines and cell-based treatments. These drugs are used across lung, breast, colorectal, prostate, blood, skin, ovarian, liver and other cancer indications.
The global cancer and oncology drugs market is expected to record strong growth through 2035. One current industry estimate projects the market to increase from approximately USD 214.70 billion in 2026 to USD 554.69 billion by 2035, representing a compound annual growth rate of 11.17%. Growth is supported by targeted treatments, developments in proteomics and continued demand for more effective cancer therapies.
The increasing global incidence of cancer is a major market driver. Population ageing, tobacco use, obesity, environmental exposure and lifestyle-related risk factors are contributing to a growing patient population. Improved screening and diagnostic technologies are also identifying more patients at earlier stages, increasing the number of individuals eligible for pharmaceutical treatment.
Targeted therapies represent an important market segment. These drugs act on specific genes, proteins or pathways involved in tumour development. Biomarker testing and companion diagnostics help physicians identify patients who are more likely to respond to particular treatments. Precision oncology is therefore increasing the connection between diagnostic testing and drug selection.
Immunotherapy continues to change cancer treatment by helping the immune system identify and attack tumour cells. Immune checkpoint inhibitors, CAR-T cell therapies and cancer vaccines are being studied across multiple solid and blood cancers. Combination therapies using immunotherapy with chemotherapy, targeted drugs or radiation are also expanding as companies seek to improve treatment response and patient survival.
Other major trends include antibody-drug conjugates, bispecific antibodies, radiopharmaceuticals and personalized cancer vaccines. Artificial intelligence is being used for target identification, molecule screening, clinical-trial planning and analysis of patient data. Biosimilars are gaining importance as patents expire for established oncology biologics, potentially improving access and increasing price competition.
Market expansion may be restrained by high treatment costs, adverse effects and unequal access to cancer care. Oncology drugs require extensive clinical testing, and unsuccessful trials can result in substantial development losses. Drug resistance may reduce long-term treatment effectiveness and create demand for additional therapies. Reimbursement restrictions and complex regulatory requirements can also delay patient access.
North America remains a major market due to high cancer treatment expenditure, research activity and access to new medicines. Europe maintains a significant position, while Asia-Pacific is expected to record strong growth as cancer incidence, healthcare investment and access to treatment increase.
Acute Market Reports provides oncology drugs market research covering drug classes, cancer indications, routes of administration, distribution channels, development pipelines, competitive conditions and regional opportunities. These reports help pharmaceutical companies, biotechnology firms, investors and healthcare organizations assess market demand and growth prospects through 2035.